A Phase 2/3 Randomized Double-Blinded Placebo-Controlled Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

Brief description of study

The main goal of this study is to see if the investigational drug is safe and effective in treating people with bullous pemphigoid (BP). The investigational drug is currently not approved for use in BP by any regulatory agency, as safety and effectiveness have not been established.

Clinical Study Identifier: s22-00078
ClinicalTrials.gov Identifier: NCT05267600
Principal Investigator: Prince Adotama.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.